Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by William C. Little
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, William C. Little wrote the following 2 articles about Coronary Artery Disease.
+ Citations + Abstracts
1 Review Evolving focus on diastolic dysfunction in patients with coronary artery disease. 2010

Ohara, Takahiro / Little, William C. ·Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1045, USA. ·Curr Opin Cardiol · Pubmed #20827179.

ABSTRACT: PURPOSE OF REVIEW: The purpose of this review is to summarize recent studies of coronary artery disease (CAD) and diastolic dysfunction. RECENT FINDINGS: Myocardial ischemia slows ventricular relaxation and can impair ventricular distensibility resulting in diastolic dysfunction apparent as abnormal left ventricular (LV) filling dynamics that can be recognized noninvasively. As such, the development of diastolic dysfunction during stress testing may improve the recognition of CAD. The noninvasive recognition of diastolic dysfunction indicates a poor prognosis in patients with an acute coronary syndrome and chronic CAD. Patients with heart failure with preserved ejection fraction (HFpEF) frequently have CAD, and it may contribute to the heart failure. SUMMARY: Myocardial ischemia produces diastolic dysfunction. The evaluation of diastolic dysfunction has diagnostic and prognostic roles in the management of CAD. CAD is a frequent and important comorbidity of HFpEF.

2 Article Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. 2018

Halbach, Marcel / Abraham, William T / Butter, Christian / Ducharme, Anique / Klug, Didier / Little, William C / Reuter, Hannes / Schafer, Jill E / Senni, Michele / Swarup, Vijay / Wachter, Rolf / Weaver, Fred A / Wilks, Seth J / Zile, Michael R / Müller-Ehmsen, Jochen. ·Department of Internal Medicine III, University Hospital of Cologne, Cologne, Germany. Electronic address: marcel.halbach@uk-koeln.de. · Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA. · Department of Cardiology, Immanuel Heart Center Bernau - Medical School Brandenburg, Bernau, Germany. · Montreal Heart Institute, University of Montréal, Montreal, Quebec, Canada. · Department of Cardiology A, University Hospital, Lille, France. · Division of Cardiology, University of Mississippi Medical Center, Jackson, MS, USA. · Department of Internal Medicine III, University Hospital of Cologne, Cologne, Germany. · Department of Statistics, NAMSA, Inc., Minneapolis, MN, USA. · Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy. · Department of Electrophysiology, Arizona Heart Hospital, Phoenix, AZ, USA. · Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany. · Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. · Department of Research, CVRx, Inc., Minneapolis, MN, USA. · Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA. · Department of Medicine, Asklepios Klinik Altona, Hamburg, Germany. ·Int J Cardiol · Pubmed #29705650.

ABSTRACT: BACKGROUND: In a randomized trial, baroreflex activation therapy (BAT) improved exercise capacity, quality of life and NT-proBNP in patients with heart failure with reduced ejection fraction (HFrEF). In view of different mechanisms underlying HFrEF, we performed a post-hoc subgroup analysis of efficacy and safety of BAT in patients with and without coronary artery disease (CAD). METHODS AND RESULTS: Patients with left ventricular ejection fraction <35% and NYHA Class III were randomized 1:1 to guideline-directed medical and device therapy alone or plus BAT. Patients with a history of CAD, prior myocardial infarction or coronary artery bypass graft were assigned to the CAD group with all others assigned to the no-CAD group. Of 71 BAT treated patients, 52 had CAD and 19 had no CAD. In the control group, 49 of 69 patients had CAD and 20 had no CAD. The system- or procedure-related major adverse neurological or cardiovascular event rate was 3.8% in the CAD group vs. 0% in the no-CAD group (p = 1.0). In the whole cohort, NYHA Class, Minnesota Living with Heart Failure score, 6-minute hall walk distance and NTproBNP were improved in BAT treated patients compared with controls. Statistical analyses revealed no interaction between the presence of CAD and effect of BAT (all p > 0.05). CONCLUSION: No major differences were found in BAT efficacy or safety between patients with and without CAD, indicating that BAT improves exercise capacity, quality of life and NTproBNP in patients with ischemic and non-ischemic cardiomyopathy. CLINICALTRIALS. GOV IDENTIFIER: NCT01471860 and NCT01720160.